Overview

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Status:
Completed

Trial end date:
2019-08-23

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate and compare the efficacy of andecaliximab (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Antibodies, Monoclonal
Nivolumab